NO20073632L - Behandling av hepatitt C med interferon-beta i en asiatisk populasjon - Google Patents

Behandling av hepatitt C med interferon-beta i en asiatisk populasjon

Info

Publication number
NO20073632L
NO20073632L NO20073632A NO20073632A NO20073632L NO 20073632 L NO20073632 L NO 20073632L NO 20073632 A NO20073632 A NO 20073632A NO 20073632 A NO20073632 A NO 20073632A NO 20073632 L NO20073632 L NO 20073632L
Authority
NO
Norway
Prior art keywords
treatment
beta
interferon
hepatitis
asian population
Prior art date
Application number
NO20073632A
Other languages
English (en)
Inventor
Theodor Wee Tit Gin
Ian Parsons
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of NO20073632L publication Critical patent/NO20073632L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Oppfinnelsen angår anvendelse av IFN-beta til fremstillingen av et medikament for behandling av en HCV-infeksjon i en behandlingsnaiv pasient som tilhører den asiatiske populasjonen.
NO20073632A 2004-12-16 2007-07-13 Behandling av hepatitt C med interferon-beta i en asiatisk populasjon NO20073632L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04106652 2004-12-16
US63787404P 2004-12-20 2004-12-20
PCT/EP2005/056793 WO2006064026A1 (en) 2004-12-16 2005-12-14 Treatment of hepatitis c in the asian population with interferon-beta

Publications (1)

Publication Number Publication Date
NO20073632L true NO20073632L (no) 2007-09-17

Family

ID=34930073

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073632A NO20073632L (no) 2004-12-16 2007-07-13 Behandling av hepatitt C med interferon-beta i en asiatisk populasjon

Country Status (12)

Country Link
US (1) US20080075696A1 (no)
EP (1) EP1824507A1 (no)
JP (1) JP2008524160A (no)
KR (1) KR20070090002A (no)
CN (1) CN101123979A (no)
AR (1) AR052165A1 (no)
AU (1) AU2005315618A1 (no)
CA (1) CA2589498A1 (no)
IL (1) IL183929A0 (no)
NO (1) NO20073632L (no)
TW (1) TW200633718A (no)
WO (1) WO2006064026A1 (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103965347B (zh) 2007-05-02 2017-07-18 Ambrx公司 经修饰干扰素β多肽和其用途
US8716454B2 (en) 2009-06-11 2014-05-06 Abbvie Inc. Solid compositions
AU2010258769C1 (en) * 2009-06-11 2016-04-28 Abbvie Ireland Unlimited Company Anti-Viral Compounds
US8937150B2 (en) 2009-06-11 2015-01-20 Abbvie Inc. Anti-viral compounds
US9394279B2 (en) * 2009-06-11 2016-07-19 Abbvie Inc. Anti-viral compounds
NZ605440A (en) 2010-06-10 2014-05-30 Abbvie Bahamas Ltd Solid compositions comprising an hcv inhibitor
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
BR112014006314A2 (pt) 2011-10-21 2017-04-11 Abbvie Inc métodos para tratamento do vírus da hepatite c (hcv) compreendendo pelo menos dois agentes antivirais de atuação direta, ribavirina, sem interferon
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
SG2014011670A (en) 2011-10-21 2014-10-30 Abbvie Inc Combination treatment (eg. with abt-072 or abt -333) of daas for use in treating hcv
US9034832B2 (en) 2011-12-29 2015-05-19 Abbvie Inc. Solid compositions
US11484534B2 (en) 2013-03-14 2022-11-01 Abbvie Inc. Methods for treating HCV
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
CN109689063B (zh) 2016-04-28 2026-02-27 埃默里大学 含有炔烃的核苷酸和核苷治疗组合物及其相关用途
KR20210100115A (ko) 2018-12-03 2021-08-13 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 올리고-벤즈아미드 유사체 및 암 치료에서의 이의 용도

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4211771A (en) * 1971-06-01 1980-07-08 Robins Ronald K Treatment of human viral diseases with 1-B-D-ribofuranosyl-1,2,4-triazole-3-carboxamide
WO1982002715A1 (fr) * 1981-02-04 1982-08-19 Sugano Haruo Gene d'interferon (beta)humain
US4737462A (en) * 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4588585A (en) * 1982-10-19 1986-05-13 Cetus Corporation Human recombinant cysteine depleted interferon-β muteins
US4959314A (en) * 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) * 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
US5017691A (en) * 1986-07-03 1991-05-21 Schering Corporation Mammalian interleukin-4
US4695195A (en) * 1986-03-05 1987-09-22 Brande Bruce R Folding boat dock
US4879111A (en) * 1986-04-17 1989-11-07 Cetus Corporation Treatment of infections with lymphokines
US4965195A (en) * 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4904584A (en) * 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
DE721983T1 (de) * 1988-01-22 2002-07-04 Zymogenetics, Inc. Verfahren zur herstellung von biologisch-aktive Dimerpeptiden
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6013253A (en) * 1997-08-15 2000-01-11 Amgen, Inc. Treatment of multiple sclerosis using consensus interferon and IL-1 receptor antagonist
AU762621B2 (en) * 1998-04-28 2003-07-03 Merck Serono Sa Polyol-IFN-beta conjugates
JP2000007578A (ja) * 1998-06-24 2000-01-11 Hiroaki Okushin Ｃ型肝炎ウイルスの陰性化のための投薬システム
US6277830B1 (en) * 1998-10-16 2001-08-21 Schering Corporation 5′-amino acid esters of ribavirin and the use of same to treat hepatitis C with interferon
TWI334785B (en) * 2002-06-03 2010-12-21 Serono Lab Use of recombinant ifn-β1a and pharmaceutical composition comprising recombinant ifn-β1a for the treatment of hcv infection in patients of asian race
MXPA05002476A (es) * 2002-09-05 2005-10-19 Gi Company Inc Asialo-interferones modificados y sus usos.
BR0314548A (pt) * 2002-09-27 2005-08-09 Biogen Idec Inc Terapias para polineuropatia de desmielinação inflamatória crÈnica empregando-se interferon-beta

Also Published As

Publication number Publication date
JP2008524160A (ja) 2008-07-10
WO2006064026A1 (en) 2006-06-22
KR20070090002A (ko) 2007-09-04
TW200633718A (en) 2006-10-01
AU2005315618A1 (en) 2006-06-22
US20080075696A1 (en) 2008-03-27
CN101123979A (zh) 2008-02-13
IL183929A0 (en) 2008-12-29
EP1824507A1 (en) 2007-08-29
CA2589498A1 (en) 2006-06-22
AR052165A1 (es) 2007-03-07

Similar Documents

Publication Publication Date Title
NO20073632L (no) Behandling av hepatitt C med interferon-beta i en asiatisk populasjon
DK1658302T3 (da) Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
DE60215157D1 (de) Verwendungen von antiviralen nucleosid-derivaten zur herstellung eines medikaments zur behandlung von hepatitis c infektionen
NO20062428L (no) Kombinasjoner for HCV-behandling
DE602005026294D1 (de) Verwendung einer kombination von cyclosporin und pegylierten interferonen zur behandlung von hepatitis c (hcv)
MA32634B1 (fr) Polytherapie destinee a traiter une infection par le vhc
BRPI0410456B8 (pt) compostos inibidores de hepatite c, composição farmacêutica, uso dos mesmos, bem como artigo de fabricação
IL195025A (en) History of compressed indolubenzazepine with cyclopropyl and pharmaceuticals containing them as an anti-hcv drug
BR112012022311A2 (pt) agentes farmacêuticos de combinação como inibidores da replicação de hcv.
WO2007089618A3 (en) Hepatitis c serine protease inhibitors and uses therefor
PE20090228A1 (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
ATE525070T1 (de) Silbininkomponente zur behandlung von hepatitis
DE60336664D1 (de) Nichtnukleosidische reverse-transkriptase-hemmer
NO20064547L (no) Fremgangsmater for behandling av HIV infeksjon
NO20034878D0 (no) Antivirale forbindelser
NO20052310L (no) Posisjonsisomerer av PEG IFN alfa 2A.
TW200633995A (en) Andrographolide derivatives to treat viral infections
IL203873A0 (en) Novel targets and compounds for therapeutic intervention of hiv infection
EA201170484A1 (ru) Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950
EP1765330A4 (en) PYRANOINDOLE DERIVATIVES AND USE THEREOF FOR THE TREATMENT OF DISEASE OR INFECTION CAUSED BY HEPATITIS C VIRUS
MXPA05008507A (es) Medicamento para enfermedad viral.
MY139068A (en) Treatment of hepatitis c in the asian population with subcutaneous interferon-beta
NO20080495L (no) PEG-IFN-alfa og ribavirin for HBV-behandling
NO20055512L (no) Terapi eller prevensjon av respiratoriske, virale infeksjoner med alfa-tyimosinpeptider
EA200602073A1 (ru) Лечение или предупреждение респираторных вирусных инфекций с помощью иммуномодуляторов

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application